REG - Arecor Therapeutics - Arecor Granted Key Canadian Patent

Arecor TherapeuticsAnnouncement

11/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211111:nRSK0205Sa&default-theme=true

RNS Number : 0205S  Arecor Therapeutics PLC  11 November 2021

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED KEY CANADIAN PATENT FOR PROPRIETARY TECHNOLOGY ENABLING HIGHLY
CONCENTRATED BIOTHERAPEUTICS

 

Cambridge, UK, 11 November 2021. Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
continues to build a strong patent portfolio protecting its proprietary
Arestat™ technology.  Arecor is pleased to announce that the Canadian
Intellectual Property Office has granted a key patent, CA2861402, with claims
protecting a specific part of the technology used in the development of
stable, low-viscosity formulations of highly concentrated protein
therapeutics, including monoclonal antibodies, fusion proteins and more
complex protein constructs.

 

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "The recently
granted Canadian patent is an important milestone in our rapidly growing
patent portfolio. We have been very successful in patenting unique
combinations of excipients that improve considerably critical quality
attributes of protein and peptide-based therapeutics, enabling their
convenient delivery. This new patent relates specifically to concentrated
protein formulations, which is one of the most challenging areas of the
biopharmaceutical drug delivery. It strengthens our IP portfolio and our
position as a world leader in the formulation of superior biotherapeutics and
vaccines."

 

The Group's Arestat™ technology enables superior product profiles across a
broad range of therapies, including various types of biopharmaceuticals,
specialty hospital products as well as vaccine compositions with improved
stability. Arecor partners with leading pharmaceutical and biotechnology
companies to deliver enhanced formulations of their therapeutic products under
a technology licensing model, as well as developing an internal portfolio of
proprietary products in diabetes and other indications.

 

A combination of high therapeutic dose and the highly desirable low injection
volume often leads to a need for very highly concentrated formulations of
protein therapeutics. Achieving such concentrated formulations can be
exceptionally challenging. The granted Canadian patent provides Arecor's
proprietary technology with broad protection in the formulation of highly
concentrated compositions of therapeutic proteins, enabling convenient
subcutaneous delivery of high value products to a higher specification
compared with other approaches. It adds to patents already issued from the
same patent family by Patent Offices in Europe, the US and India.

Arecor has invested in building a strong patent portfolio to protect the
Arestat™ technology platform. The Group's intellectual property portfolio
currently comprises 33 patent families, including >50 granted patents in
Europe in the US and in other key territories.

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFBLLFFFLLFBD